Tuesday, July 16, 2024

Digital Therapeutics Revolutionize Non-Specific Low Back Pain Management: The Rise-uP Trial

Similar articles

In today’s rapidly advancing digital age, the Rise-uP trial emerges as a beacon of innovation in the management of non-specific low back pain (NLBP). By integrating the Kaia back pain app into a general practitioner-centric approach, this study charts a new course in both clinical and economic outcomes for patients. Over 12 months, the trial evaluated not just the clinical efficacy but also patient satisfaction and economic ramifications, underscoring the transformative potential of digital therapeutics.

Study Design and Methodology

The cluster-randomized controlled trial involved 1237 participants, with 930 patients receiving the Rise-uP treatment and 307 undergoing standard care. Pain levels, psychological well-being, functional capacity, and other patient-reported outcome measures (PROMs) were assessed at multiple intervals: baseline, 3, 6, and 12 months. Health costs were meticulously tracked with the collaboration of health insurance providers AOK, DAK, and BARMER. Additionally, an AI-driven behavioral analysis identified four distinct app usage patterns, all yielding similar clinical outcomes.

Clinical and Economic Outcomes

The results were compelling. Patients in the Rise-uP group reported a 46% reduction in pain at 12 months, significantly higher than the 24% reduction in the control group. This pain reduction was not just statistically significant but also clinically meaningful. Beyond pain reduction, the Rise-uP group showed superior results in all other PROMs. The AI analysis revealed that varying levels of app engagement—from short to long-term use—consistently produced similar improvements in pain levels, suggesting flexible yet effective app utilization.

Moreover, the economic analysis highlighted the cost-effectiveness of the Rise-uP approach. The integration of the Kaia app into the treatment regimen resulted in substantial economic benefits, making a strong case for its widespread adoption. The combination of clinical benefits and economic advantages suggests a promising avenue for enhancing market access for digital therapeutics in NLBP management.

Key Inferences

Valuable insights from the study include:

  • Significant clinical improvement in pain reduction and overall patient well-being with the Rise-uP approach.
  • Economic analysis reveals the cost-effectiveness of integrating digital therapeutics into standard care.
  • AI-driven behavioral analysis shows consistent clinical outcomes across different levels of app usage.
  • High patient satisfaction underscores the acceptability of digital therapeutics.

The Rise-uP trial demonstrates that integrating a multimodal back pain app within a general practitioner framework can significantly improve clinical and economic outcomes for NLBP patients. This approach not only offers superior pain management but also reduces healthcare costs, making it a viable option for broader market access in digital health interventions.

Original Article:

J Pain Res. 2024 Jun 26;17:2239-2255. doi: 10.2147/JPR.S473250. eCollection 2024.


You can follow our news on our Telegram and LinkedIn accounts.

PURPOSE: Non-specific low back pain (NLBP) exerts a profound impact on global health and economics. In the era of Web 3.0, digital therapeutics offer the potential to improve NLBP management. The Rise-uP trial introduces a digitally anchored, general practitioner (GP)-focused back pain management approach with the Kaia back pain app as the key intervention. Here, we present the 12-months evaluation of the Rise-uP trial including clinical and economic outcomes, patient satisfaction and behavioral tracking analysis.

METHODS: The cluster-randomized controlled study (registration number: DRKS00015048) enrolled 1237 patients, with 930 receiving treatment according to the Rise-uP approach and 307 subjected to standard of care treatment. Assessments of pain, psychological state, functional capacity, and well-being (patient-reported outcome measures; PROMs) were collected at baseline, and at 3-, 6-, and 12-months follow-up intervals. Health insurance partners AOK, DAK, and BARMER provided individual healthcare cost data. An artificial intelligence (AI)-driven behavioral tracking analysis identified distinct app usage clusters that presented all with about the same clinical outcome. Patient satisfaction (patient-reported experience measures; PREMs) was captured at the end of the trial.

RESULTS: Intention-to-treat (ITT) analysis demonstrated that the Rise-uP group experienced significantly greater pain reduction at 12 months compared to the control group (IG: -46% vs CG: -24%; p < 0.001) with only the Rise-uP group achieving a pain reduction that was clinically meaningful. Improvements in all other PROMs were notably superior in patients of the Rise-uP group. The AI analysis of app usage discerned four usage clusters. Short- to long-term usage, all produced about the same level of pain reduction. Cost-effectiveness analysis indicated a substantial economic benefit for Rise-uP.

CONCLUSION: The Rise-uP approach with a medical multimodal back pain app as the central element of digital treatment demonstrates both, clinical and economic superiority compared to standard of care in the management of NLBP.

PMID:38952994 | PMC:PMC11215667 | DOI:10.2147/JPR.S473250

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article